Literature DB >> 24055348

Bovine papillomavirus-like particles presenting conserved epitopes from membrane-proximal external region of HIV-1 gp41 induced mucosal and systemic antibodies.

Yougang Zhai1, Zhenyu Zhong, Mohammadreza Zariffard, Gregory T Spear, Liang Qiao.   

Abstract

Two conserved epitopes, located in the membrane-proximal external region (MPER) of the human immunodeficiency virus type 1 (HIV-1) gp41, are recognized by two HIV-1 broadly neutralizing antibodies 2F5 and 4E10, and are promising targets for vaccine design in efforts to elicit anti-HIV-1 broadly neutralizing antibodies. Since most HIV-1 infections initiate at mucosal surfaces, induction of mucosal neutralizing antibodies is necessary and of utmost importance to counteract HIV-1 infection. Here, we utilized a mucosal vaccine vector, bovine papillomavirus (BPV) virus-like particles (VLPs), as a platform to present HIV-1 neutralizing epitopes by inserting the extended 2F5 or 4E10 epitope or the MPER domain into D-E loop of BPV L1 respectively. The chimeric VLPs presenting MPER domain resembled the HIV-1 natural epitopes better than the chimeric VLPs presenting single epitopes. Oral immunization of mice with the chimeric VLPs displaying the 2F5 epitope or MPER domain elicited epitope-specific serum IgGs and mucosal secretory IgAs. The induced antibodies specifically recognized the native conformation of MPER in the context of HIV-1 envelope protein. The antibodies induced by chimeric VLPs presenting MPER domain are able to partially neutralize HIV-1 viruses from clade B and clade C.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Bovine papillomavirus-like particle; HIV-1; Membrane-proximal external region; Mucosal; Neutralizing antibody; Vaccine

Mesh:

Substances:

Year:  2013        PMID: 24055348      PMCID: PMC3881962          DOI: 10.1016/j.vaccine.2013.09.003

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  54 in total

1.  Broad HIV-1 neutralization mediated by CD4-binding site antibodies.

Authors:  Yuxing Li; Stephen A Migueles; Brent Welcher; Krisha Svehla; Adhuna Phogat; Mark K Louder; Xueling Wu; George M Shaw; Mark Connors; Richard T Wyatt; John R Mascola
Journal:  Nat Med       Date:  2007-08-26       Impact factor: 53.440

2.  Structural details of HIV-1 recognition by the broadly neutralizing monoclonal antibody 2F5: epitope conformation, antigen-recognition loop mobility, and anion-binding site.

Authors:  Jean-Philippe Julien; Steve Bryson; Jose L Nieva; Emil F Pai
Journal:  J Mol Biol       Date:  2008-09-18       Impact factor: 5.469

3.  Structural basis of enhanced binding of extended and helically constrained peptide epitopes of the broadly neutralizing HIV-1 antibody 4E10.

Authors:  Rosa M F Cardoso; Florence M Brunel; Sharon Ferguson; Michael Zwick; Dennis R Burton; Philip E Dawson; Ian A Wilson
Journal:  J Mol Biol       Date:  2006-11-10       Impact factor: 5.469

4.  Analysis of the human immunodeficiency virus type 1 gp41 membrane proximal external region arrayed on hepatitis B surface antigen particles.

Authors:  S Phogat; K Svehla; M Tang; A Spadaccini; J Muller; J Mascola; I Berkower; R Wyatt
Journal:  Virology       Date:  2007-12-26       Impact factor: 3.616

5.  Broad neutralization of human immunodeficiency virus type 1 (HIV-1) elicited from human rhinoviruses that display the HIV-1 gp41 ELDKWA epitope.

Authors:  Gail Ferstandig Arnold; Paola K Velasco; Andrew K Holmes; Terri Wrin; Sheila C Geisler; Pham Phung; Yu Tian; Dawn A Resnick; Xuejun Ma; Thomas M Mariano; Christos J Petropoulos; John W Taylor; Hermann Katinger; Eddy Arnold
Journal:  J Virol       Date:  2009-03-11       Impact factor: 5.103

6.  Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand.

Authors:  Supachai Rerks-Ngarm; Punnee Pitisuttithum; Sorachai Nitayaphan; Jaranit Kaewkungwal; Joseph Chiu; Robert Paris; Nakorn Premsri; Chawetsan Namwat; Mark de Souza; Elizabeth Adams; Michael Benenson; Sanjay Gurunathan; Jim Tartaglia; John G McNeil; Donald P Francis; Donald Stablein; Deborah L Birx; Supamit Chunsuttiwat; Chirasak Khamboonruang; Prasert Thongcharoen; Merlin L Robb; Nelson L Michael; Prayura Kunasol; Jerome H Kim
Journal:  N Engl J Med       Date:  2009-10-20       Impact factor: 91.245

7.  HIV-1 broadly neutralizing antibody extracts its epitope from a kinked gp41 ectodomain region on the viral membrane.

Authors:  Zhen-Yu J Sun; Kyoung Joon Oh; Mikyung Kim; Jessica Yu; Vladimir Brusic; Likai Song; Zhisong Qiao; Jia-huai Wang; Gerhard Wagner; Ellis L Reinherz
Journal:  Immunity       Date:  2008-01       Impact factor: 31.745

8.  HIV-1 gp41-specific monoclonal mucosal IgAs derived from highly exposed but IgG-seronegative individuals block HIV-1 epithelial transcytosis and neutralize CD4(+) cell infection: an IgA gene and functional analysis.

Authors:  D Tudor; M Derrien; L Diomede; A-S Drillet; M Houimel; C Moog; J-M Reynes; L Lopalco; M Bomsel
Journal:  Mucosal Immunol       Date:  2009-07-08       Impact factor: 7.313

9.  Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target.

Authors:  Laura M Walker; Sanjay K Phogat; Po-Ying Chan-Hui; Denise Wagner; Pham Phung; Julie L Goss; Terri Wrin; Melissa D Simek; Steven Fling; Jennifer L Mitcham; Jennifer K Lehrman; Frances H Priddy; Ole A Olsen; Steven M Frey; Phillip W Hammond; Stephen Kaminsky; Timothy Zamb; Matthew Moyle; Wayne C Koff; Pascal Poignard; Dennis R Burton
Journal:  Science       Date:  2009-09-03       Impact factor: 47.728

10.  Identification of autoantigens recognized by the 2F5 and 4E10 broadly neutralizing HIV-1 antibodies.

Authors:  Guang Yang; T Matt Holl; Yang Liu; Yi Li; Xiaozhi Lu; Nathan I Nicely; Thomas B Kepler; S Munir Alam; Hua-Xin Liao; Derek W Cain; Leonard Spicer; John L VandeBerg; Barton F Haynes; Garnett Kelsoe
Journal:  J Exp Med       Date:  2013-01-28       Impact factor: 14.307

View more
  14 in total

1.  Central nervous system-specific consequences of simian immunodeficiency virus Gag escape from major histocompatibility complex class I-mediated control.

Authors:  Sarah E Beck; Suzanne E Queen; Raphael Viscidi; Darius Johnson; Stephen J Kent; Robert J Adams; Patrick M Tarwater; Joseph L Mankowski
Journal:  J Neurovirol       Date:  2016-01-04       Impact factor: 2.643

2.  Standardization of a cytometric p24-capture bead-assay for the detection of main HIV-1 subtypes.

Authors:  Mélanie Merbah; Sayali Onkar; Jean-Charles Grivel; Christophe Vanpouille; Angélique Biancotto; Lydia Bonar; Eric Sanders-Buell; Gustavo Kijak; Nelson Michael; Merlin Robb; Jerome H Kim; Sodsai Tovanabutra; Agnès-Laurence Chenine
Journal:  J Virol Methods       Date:  2016-01-22       Impact factor: 2.014

Review 3.  Demystifying particle-based oral vaccines.

Authors:  Pedro Gonzalez-Cruz; Harvinder Singh Gill
Journal:  Expert Opin Drug Deliv       Date:  2021-07-06       Impact factor: 8.129

4.  DNA Vaccine-Encoded Flagellin Can Be Used as an Adjuvant Scaffold to Augment HIV-1 gp41 Membrane Proximal External Region Immunogenicity.

Authors:  Lara Ajamian; Luca Melnychuk; Patrick Jean-Pierre; Gerasimos J Zaharatos
Journal:  Viruses       Date:  2018-02-27       Impact factor: 5.048

5.  Papilloma-pseudovirus eradicates intestinal tumours and triples the lifespan of ApcMin/+ mice.

Authors:  Zhenyu Zhong; Yougang Zhai; Ping Bu; Shivanee Shah; Liang Qiao
Journal:  Nat Commun       Date:  2017-04-11       Impact factor: 14.919

Review 6.  The development of HIV vaccines targeting gp41 membrane-proximal external region (MPER): challenges and prospects.

Authors:  Huan Liu; Xiaojie Su; Lulu Si; Lu Lu; Shibo Jiang
Journal:  Protein Cell       Date:  2018-04-17       Impact factor: 14.870

7.  Development and immunological assessment of VLP-based immunogens exposing the membrane-proximal region of the HIV-1 gp41 protein.

Authors:  Thomas D Benen; Paul Tonks; Alexander Kliche; Ruth Kapzan; Jonathan L Heeney; Ralf Wagner
Journal:  J Biomed Sci       Date:  2014-08-27       Impact factor: 8.410

Review 8.  Current Advances in Virus-Like Particles as a Vaccination Approach against HIV Infection.

Authors:  Chongbo Zhao; Zhujun Ao; Xiaojian Yao
Journal:  Vaccines (Basel)       Date:  2016-01-22

9.  Enhancing antitumor immunogenicity of HPV16-E7 DNA vaccine by fusing DNA encoding E7-antigenic peptide to DNA encoding capsid protein L1 of Bovine papillomavirus.

Authors:  Andrew Yang; Shiwen Peng; Emily Farmer; Qi Zeng; Max A Cheng; Xiaowu Pang; T-C Wu; Chien-Fu Hung
Journal:  Cell Biosci       Date:  2017-08-23       Impact factor: 7.133

Review 10.  Immunologic Insights on the Membrane Proximal External Region: A Major Human Immunodeficiency Virus Type-1 Vaccine Target.

Authors:  Luis M Molinos-Albert; Bonaventura Clotet; Julià Blanco; Jorge Carrillo
Journal:  Front Immunol       Date:  2017-09-19       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.